V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,027

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

MeaslesMumpsRubellaVaricella

Interventions

BIOLOGICAL

Comparator: ProQuad™ (V221)

0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)

BIOLOGICAL

Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)

0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00109343 - V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) | Biotech Hunter | Biotech Hunter